

ECI's announcement at the 44th annual conference of the Japanese Cancer Association regarding anticancer therapy through a combination treatment of eMIP and radiation is awarded the iPos Award

The Effector Cell Institute, Inc. led by president Shiro Kanegasaki is researching anticancer therapy involving eMIP, a derivative of MIP-1 α .

ECI made an announcement at the 11th International Congress of Metastasis Research Society in September regarding the magnification of the abscopal effect and increased effect of radiation on the tumor due to simultaneous weekly eMIP administration.

Through further experimentation, it has become apparent that by administering eMIP for five consecutive days, its effect on reducing tumors was increased further and also had a life-prolonging effect. The complete presentation was shown at the the 44th annual conference of the Japanese Cancer Association which took place at the Keio Plaza Hotel, October 18-20. ECI's collaborative researcher, Assistant Professor Kenshiro Shiraishi of the Department of Radiology at the Graduate School of Medicine at the University of Tokyo was awarded the iPos Award for this presentation.

These new discoveries were also made possible by collaborative research of Associate Professor Keiichi Nakagawa and Professor Koji Matsushima at Departments of Radiology and Molecular Preventative Medicine, Graduate School of Medicine, University of Tokyo.

At the ECI laboratories, preparations for formulation of eMIP at a GMP level as well as entry into clinical trials are underway. Due to eMIP's potential of becoming a novel anticancer drug which limits metastasis and magnifies the effect of radiation therapy, there is an increasing interest from American national research institutions. Currently, we are progressing with the eMIP project by seeking to tie a contract which will allow for clinical trials in the United States.

< Reference Information >

[Vocabulary]

iPos Award:	An award recognizing the excellence of a presentation by use of the ideal Presentation Online System
Abscopal effect:	The phenomenon where radiation on one tumor affects tumors at other locations in the body, reducing them in size or eliminating them all together. (The mechanism of this effect is thought to be directed by various effector cells.)
eMIP:	A variant of chemotactic factor MIP-1 α . It has been shown that this recombinant protein enhances anticancer effects.
chemotaxis:	The movement of cells induced by changing concentrations of certain chemical compounds. Such chemical compounds are called "chemotactic factors."